Harris Erik — SEC Form 4 filings
SEC reporting owner CIK 1780113. 8 Form 4 filings on record with FilingPulse; latest filed 2026-04-20.
Transaction summary — filings shown
Covers all 8 filings on record, filed 2024-03-05 to 2026-04-20. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 3 legs across 3 filings — 30,410 shares, $1,132,453 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 15.
- Largest priced transaction: sale of 15,103 shares @ $42.10 ($635,836) in Ultragenyx Pharmaceutical Inc., filed 2025-03-04.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | EVP & Chief Commercial Officer | 4 | — | 3 legs · 30,410 sh · $1,132,453 | 9 |
| Rezolute, Inc. (RZLT) | Director | 2 | — | — | 3 |
| Denali Therapeutics Inc. (DNLI) | Director | 1 | — | — | 2 |
| Inozyme Pharma, Inc. (INZY) | Director | 1 | — | — | 1 |
Form 4 filings — Harris Erik
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-04-20 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 28,895 @ $0 · Grant/award (A): 49,960 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 11,643 @ $0 · Sale (S): 10,539 @ $22.80 | EDGAR |
| 2025-11-21 | 4 | Rezolute, Inc. (RZLT) | Grant/award (A): 21,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-03-26 | 4 | Rezolute, Inc. (RZLT) | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 16,813 @ $0 · Grant/award (A): 18,443 @ $0 · Sale (S): 15,103 @ $42.10 · Grant/award (A): 30,246 (derivative) @ $0 | EDGAR |
| 2024-10-07 | 4 | Inozyme Pharma, Inc. (INZY) | Grant/award (A): 56,000 (derivative) @ $0 | EDGAR |
| 2024-06-04 | 4 | Denali Therapeutics Inc. (DNLI) | Grant/award (A): 5,967 @ $0 · Grant/award (A): 17,901 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 19,400 @ $0 · Grant/award (A): 957 @ $0 · Sale (S): 4,768 @ $53.76 · Grant/award (A): 34,200 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1780113 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →